IPSEN
Ipsen S.A. operates as a biopharmaceutical company worldwide. It operates in two segments, Specialty Care and Consumer Healthcare. The company offers drugs in the areas of oncology, neuroscience, pituitary pathologies and growth disorders, gastrointestinal disorders, neurodegenerative pathologies, and rheumatology. Its products include Somatuline for neuroendocrine tumors and acromegaly; Cabometyx to treat renal cell and second-line hepatocellular carcinoma; Onivyde for metastatic pancreatic cancer; Decapeptyl to treat advanced metastatic prostate cancer, uterine fibroids, precocious puberty, endometriosis, female sterility, and early stage breast cancer; and Dysport for motor muscular disorders and medical aesthetics. The company also provides NutropinAq to treat growth failure in children due to growth hormone deficiency, turner syndrome, or chronic renal failure, as well as GH deficiency in adults; and Increlex for long-term treatment of growth failure in children and adolescents. In addition, it offers Smecta for the treatment of chronic and acute diarrhea, and pain linked to oesogastroduodenal conditions and colic; Forlax for constipation; and Fortrans/Eziclen for intestinal cleaning; Etiasa for inflammatory bowel diseases; and Tanakan to treat mild cognitive impairment related to age, pathophysiological deficiencies, vertigo, retinal deficits, acute or chronic hearing impairment, and tinnitus. Further, the company provides Adenuric for chronic hyperuricaemia; Prontalgine, an analgesic to treat moderate to severe pain; Buscopan, an antispasmodic; Suppositoria Glycerini, a laxative; and Mucothiol and Mucodyne, which are expectorants for cough and flu. The company has a strategic agreement with Arix Bioscience plc; and a global licensing and joint development agreement with The University of Texas MD Anderson Cancer Center. Ipsen S.A. was founded in 1929 and is headquartered in Boulogne-Billancourt, France. Ipsen S.A. is a subsidiary of Mayroy S.A. Show More...
-
Website http://www.ipsen.com
-
Sector Healthcare
-
Industry Drug Manufacturers-Specialty & Generic
-
Last Quote 103.70 EUR
-
Last Updated 30-05-2025
-
External Links Yahoo Finance Morningstar Ratios
-
Interest Coverage
The interest coverage ratio is a debt ratio and profitability ratio used to determine how easily a company can pay interest on its outstanding debt.
Reference: Investopedia -
2010-12 2011-12 2012-12 2013-12 2014-12 2015-12 2016-12 2017-12 2018-12 2019-12 TTM Earnings Per Share EUR 1.13 0.010 -0.34 1.83 1.87 2.3 2.73 3.28 4.68 -0.61 -0.61 Dividends EUR 0.75 0.8 0.8 0.8 0.8 0.85 0.85 0.85 1.0 1.0 1.0 Payout Ratio % * 66.4 60.2 70.2 78.4 42.3 50.3 30.3 32.4 24.2 20.6 Shares Mil 85.0 83.0 83.0 83.0 82.0 83.0 83.0 83.0 83.0 84.0 84.0 Book Value Per Share * EUR 12.97 12.74 11.13 11.31 11.94 13.78 15.23 16.93 20.05 23.86 21.08 Free Cash Flow Per Share * EUR 1.98 1.31 0.74 0.88 1.38 1.77 0.43 0.63 3.37 3.24 Return on Assets % 5.85 0.03 -1.85 9.76 9.36 10.4 10.36 9.91 12.08 -1.32 -1.32 Financial Leverage (Average) 1.56 1.61 1.69 1.61 1.61 1.59 1.78 2.01 1.83 2.46 2.46 Return on Equity % 9.25 0.04 -3.04 16.09 15.07 16.6 17.5 18.88 23.14 -2.82 -2.82 Return on Invested Capital % 9.03 0.15 -2.71 16.26 15.25 16.61 14.4 15.75 19.41 -1.29 -1.29 Interest Coverage 80.11 24.53 23.38 38.72 35.97 61.85 43.54 34.1 49.43 -0.23 -0.23 Current Ratio 1.92 1.71 1.39 1.6 1.64 1.75 1.87 1.08 1.23 0.93 0.93 Quick Ratio 1.26 1.09 0.87 1.03 1.08 1.23 1.44 0.75 0.87 0.69 0.69 Debt/Equity 0.010 0.02 0.22 0.2 0.16 0.32 0.32